STICs And STONes: A Randomised, Phase II, Double-Blind, Placebo-Controlled Trial Of Aspirin In Chemoprevention Of Ovarian Cancer In Women With BRCA1 And BRCA2 Mutations
Funder
National Health and Medical Research Council
Funding Amount
$653,892.00
Summary
Women with a BRCA1 or BRCA2 gene abnormality are at increased risk of ovary and fallopian tube (O&FT) cancers and often have their O&FTs removed to prevent cancer. Microscopic cancers are often seen at the time of surgery. Some studies suggest that aspirin might reduce O&FT cancer risk. This study will assign women to daily aspirin or placebo for 6-24 months before their preventive O&FT surgery. It will provide a better understanding of how O&FT cancers start and the influence aspirin may have.
Evaluation Of Unclassified Variants Of BRCA1 And BRCA2 Using A Multifactorial Approach
Funder
National Health and Medical Research Council
Funding Amount
$456,495.00
Summary
The major genes that predispose to hereditary breast cancer are called BRCA1 and BRCA2. Most mutations in these genes cause the protein product to be truncated and inactive. However there are many families in which such truncating mutations are not found, but instead there are sequence changes that may slightly alter the protein product. It is often difficult to predict whether these sequence variants are likely to cause hereditary breast cancer simply by looking at the position and nature of th ....The major genes that predispose to hereditary breast cancer are called BRCA1 and BRCA2. Most mutations in these genes cause the protein product to be truncated and inactive. However there are many families in which such truncating mutations are not found, but instead there are sequence changes that may slightly alter the protein product. It is often difficult to predict whether these sequence variants are likely to cause hereditary breast cancer simply by looking at the position and nature of the sequence change. Consequently, it is not possible to offer informative genetic counselling to these women or their at-risk family members. Assessment of the potential pathogenicity and functional significance of these unclassified sequence variants will be directly useful with regard to the clinical management of these women and their families, and will develop our current understanding of how different domains of these genes contribute to their role as cancer susceptibility genes. In addition, some of our experiments to classify variants may be useful as a screening tool to identify carriers of mutations, and so prioritize them for mutation screening.Read moreRead less